Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: PG 490

Latest Information Update: 24 Jan 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories; Fujian Institute of Medical Science; Harold C. Simmons Arthritis Research Center; National Cancer Center (Tokyo); Pharmagenesis; Stanford University; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Diterpenes; Epoxy compounds; Phenanthrenes
  • Mechanism of Action Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer; Inflammation; Rheumatoid arthritis; Solid tumours; Transplant rejection

Most Recent Events

  • 13 Jun 2002 A preclinical study has been added to the Cancer pharmacodynamics section
  • 18 Apr 2002 No development reported - Preclinical for Inflammation in China (unspecified route)
  • 18 Apr 2002 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top